P3 Health Partners (PIII) Q2 2025 Earnings
How Did PIII Stock React to Q2 2025 Earnings?
S&P 500 over the same 30 days: +2.45%.
Did PIII Beat Earnings? Q2 2025 Results
P3 Health Partners delivered a disappointing second quarter, posting revenue of $355.79 million, a 6.2% decline year-over-year that fell short of the $359.43 million consensus estimate by roughly 1%, while a diluted loss per share of $6.23 stood in stark contrast to the breakeven expectation on Wall Street. The primary culprit was a wave of prior-period adjustments tied to payer settlements, which compressed medical margin to $30.61 million; stripping out those items, medical margin would have reached $39.30 million, a figure management says better reflects the company's operational trajectory. Interest expense nearly doubled to $10.14 million from $5.44 million a year ago, amplifying pressure on a balance sheet already navigating going concern risks. In response, P3 cut its full-year 2025 guidance, now projecting revenues of $1.35 billion to $1.50 billion and an Adjusted EBITDA loss of $69 million to $39 million, citing a single underperforming payer relationship. Still, management pointed to flat medical cost trends and $120 million to $170 million in identified EBITDA improvement opportunities as reasons for confidence in reaching sustained profitability by 2026.
- Flat medical cost trends despite industry-wide inflation
- 10% improvement in per-member funding year-over-year when adjusted for prior-period items
- Network and payer rationalization driving 9% decline in at-risk membership
- Three of four markets already EBITDA positive or breakeven
“Our core business continues to strengthen as we execute on our $130 million EBITDA improvement plan. While we faced prior period headwinds, we've successfully managed medical cost trends to remain flat while improving funding across our membership on a per-member basis. With an additional $120 to $170 million in identified EBITDA opportunities and three of our four markets already EBITDA positive or breakeven, P3 is well-positioned to achieve sustained profitability in 2026 and beyond.”
P3 Health Partners CEO, on the earnings call
What Was P3 Health Partners's Outlook in Q2 2025?
P3 revised its full-year 2025 guidance downward to reflect prior-period adjustment impacts and underperformance of a single payer. The company now expects at-risk members of 109,000-119,000, total revenues of $1,350-$1,500 million, medical margin of $124-$154 million ($90-$111 PMPM), and Adjusted EBITDA loss of ($69)-($39) million. Management identified $120-$170 million in additional EBITDA improvement opportunities for 2026 and stated P3 is well-positioned to achieve sustained profitability in 2026 and beyond, with three of four markets already EBITDA positive or breakeven.
PIII YoY Financials
| Metric | Q2 2025 | Q2 2024 | Year over year |
|---|---|---|---|
| Revenue | $355.8M | $379.1M | −6.2% |
| Gross Profit | $4.4M | $14.0M | −68.3% |
| Operating Income | −$34.1M | −$37.5M | −8.9% |
PIII Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.